Table Of Content

Author Index for Volume 29 Note: Page numbers preceded by S indicate May/June supplement. A Hamilton C, 74 Phillips $, 266 Ahlin C, 253 Hankins J, 260 Poole SK, 151 Alexander M, 7, 57, 127, 183, 197, 245 Hellstrém B, 253 Arvanitis D, 101 Hicks RW, 20 R Huebsch LB, 81 Reid B, 158 B J Becker SC, 20 S Jacobs BR, 28 Belcher D, 63 Scarlet ¢ + 39 Berreth M, 195 Johansson E, 253 Scerbo MW, 214 Bliss JP, 214 Schears GJ, 34, 225 Boissonneault N, 158 K Schmidt EA, 214 Brundin S, 253 Kirmse J], $15 Schultz AA, 338 Klang-Séderkvist B, 253 Seidner D, 74 7» Knue M, 28 Sejismundo LP, 272 Cypher S, 318 Kobrynski L], 206 Smith B, 14 Czaplewski LM, 2 Koski CL, $21 Stafford ], 74 Steiger E, 74 D Stowell CP, $29 de Burgoa L], 74 LaGrange CA, 158 T Doellman D, 28 Lamondy AM, 89 Dutt K, $5 Left L, 326 Trotochaud K, 165 iz M V Farraj R, 101 McDiarmid S, 81 Van Allen, D, 158 Frey AM, 34 Viale PH, 283 Fugate JH, 147 N Vizearra C, 63 Nash P, 346 G Nowobilski-Vasilios A, 151 W Gallant P, 338 Walker SR, 101 Walsh M, 192 P H Papavassiliou V, 101 Hadaway L, 137 Patterson JV, S21 Hamelin L, 81 Petterson K, 253 Journal of Infusion Nursing Author Index for Volume 29 Note: Page numbers preceded by S indicate May/June supplement. A Hamilton C, 74 Phillips $, 266 Ahlin C, 253 Hankins J, 260 Poole SK, 151 Alexander M, 7, 57, 127, 183, 197, 245 Hellstrém B, 253 Arvanitis D, 101 Hicks RW, 20 R Huebsch LB, 81 Reid B, 158 B J Becker SC, 20 S Jacobs BR, 28 Belcher D, 63 Scarlet ¢ + 39 Berreth M, 195 Johansson E, 253 Scerbo MW, 214 Bliss JP, 214 Schears GJ, 34, 225 Boissonneault N, 158 K Schmidt EA, 214 Brundin S, 253 Kirmse J], $15 Schultz AA, 338 Klang-Séderkvist B, 253 Seidner D, 74 7» Knue M, 28 Sejismundo LP, 272 Cypher S, 318 Kobrynski L], 206 Smith B, 14 Czaplewski LM, 2 Koski CL, $21 Stafford ], 74 Steiger E, 74 D Stowell CP, $29 de Burgoa L], 74 LaGrange CA, 158 T Doellman D, 28 Lamondy AM, 89 Dutt K, $5 Left L, 326 Trotochaud K, 165 iz M V Farraj R, 101 McDiarmid S, 81 Van Allen, D, 158 Frey AM, 34 Viale PH, 283 Fugate JH, 147 N Vizearra C, 63 Nash P, 346 G Nowobilski-Vasilios A, 151 W Gallant P, 338 Walker SR, 101 Walsh M, 192 P H Papavassiliou V, 101 Hadaway L, 137 Patterson JV, S21 Hamelin L, 81 Petterson K, 253 Journal of Infusion Nursing Note: Page numbers preceded by SJ indicate the January/February supplement (INS Standards of Practice), and those preceded by SM indicate the May/June supplement. Cancer, chemotherapy for, nausea and vom hemotherapy, nausea and vomiting in, 283 Abatacept, for rheumatoid arthritis, 326 iting in, 283 o~ hildren Adalimumab, for rheumatoid arthritis, 326 Cardiac emergencies, pharmacologic man combined immune deficiencies in, 206 agement of, 147 peripherally inserted central catheters Adhesive tape, vs. securement devices, 34, 75 Catheter(s for, 28 Albumin, in fluid and electrolyte balance, 260 central venous hronic inflammatory neuropathies, IV im peripherally inserted, vs. Hickman munoglobulin for, SM21 Anakinra, for rheumatoid arthritis, 326 Anaphylaxis, 39 catheter, for autologous olony-stimulating factors, 147 Antiarrhythmicsf,o r cardiac emergencies, 147 stem cell transplant, 81 ombined immune deficiencies, in children, Anticytokines, for rheumatoid arthritis, 32¢ written protocol for, 253 206 flushing techniques for, 137 ontinuing education, 293, SM45 Antiemetics peripheral intravenous CRNI Recertification, review questions for, in chemotherapy, 283 discontinuation of, Visual Infusion 293, SM45 in pregnancy, 59 Argatroban, for heparin-induced thrombo Phlebitis scale for, 338 cytopenia, 318 dwell times for, 14 D Arrhythmias, pharmacologic management management practices for, in Darbopoietin alpha, 147 Greek, Jordanian, and Aus of, 147 Defibrillation, 147 tralian teaching hospitals, Arthritis, rheumatoid, emerging new thera Dermatomyositis, [V immunoglobulin for, 101 pies for 326 SM21 peripherally inserted central Asystole, pharmacologic management of, 147 in children, 28 DiGeorge syndrome, 206 Australia, peripheral intravenous catheter Disease-modifying antirheumatic drugs, for securement devices for, 34, 225 management practices in, 101 rheumatoid arthritis, 326 vs. Hickman catheter, for autolo Autologous stem cell transplantation, Hick Drug abuse, ethical aspects of, 266 gous stem cell transplant, man vs. peripherally inserted 81 central catheter for, 81 E securement devices for, 34, 225 B umbilical, placement and complica Editorials, 7, 57, 127, 183, 245, 309 tion management for, 346 Education and training Biologic infusion therapy CathSim system, for phlebotomy training, continuing education review ques for rheumatoid arthritis, 214 tions for, 293, SM45 for vasculitis, 272 Central venous catheters. See also phlebotomy, virtual reality simulator monoclonal antibodies in, SM39 Catheter(s) vs. simulated limbs for, 214 parenteral, 63 peripherally inserted written protocol for central venous Bradycardia, pharmacologic management of, for autologous stem cell trans catheters in, 253 147 plant, 81 Electrocardiogram, in cardiac emergencies, in children, 28 147 C securement devices for, 34, 225 Enteral nutrition, for hyperemesis gravi Canada, protocol recommendations for IV vs. Hickman catheter, for autolo darum, 89 immunoglobulin administra gous stem cell transpiant, 81 Erythropoietin alpha, 147 tion in, 158 written protocol for, 253 2 Etanercept, for rheumatoid arthritis, 326 360 ° Journal of Infusion Nursing Ethical issues L Polymyositis, [V immunoglobulin for, SM21 in access to healthcare, 165 Lambert Eaton myasthenic syndrome, IV im- Pregnancy, hyperemesis in, 89 in substance abuse, 266 munoglobulin for, SM21 Pulseless electrical activity, pharmacologic Lewis Sumner syndrome, IV immunoglobu- management of, 147 lin for, SM21 Pumps, flushing, 137 Fixation devices, 34, 225 Fluuiidd and 1 eleeleccttrroollyyttee bbaall ance, alIkb umin in, M R 260 Medication error reporting program, 20 Reporting, of medication errors, Flushing techniques, 137 MEDMARX program, 20 MEDMARX program for, 20 Monoclonal antibodies, $M39 Rheumatoid arthritis, emerging new thera- G for rheumatoid arthritis, 326 pies for, 326 Granulocyte colony-stimulating factors, 147 for vasculitis, 272 Rituximab. See also Monoclonal antibodies Granulocyte-macrophage coloiy-stimulating parenteral administration of, 63 for rheumatoid arthritis, 326 factors, 147 Multifocal motor neuropathy, IV im- for vasculitis, 272 Greece, peripheral intravenous catheter man munoglobulin for, SM21 agement practices in, 101 Myasthenia gravis, IV immunoglobulin for, S SM21 Securement devices, 34, 225 H Myositis, inclusion body, IV immunoglobu Severe combined immunodeficiency, 206 Healthcare access, ethical aspects of, 165 lin for, SM21 Simulated limbs, vs. virtual reality simulator, Heart disease, emergency pharmacologic for phlebotomy training, 214 management in, 147 N Standards of practice Heparin-induced thrombocytopenia, arga- Nausea and vomiting for access devices, $]45 troban for, 318 in chemotherapy, 283 for documentation, $]18 Hickman catheter, vs. peripherally inserted severe, in pregnancy, 89 for infection control and safety com- central catheter, for autolo- Needleless injection systems, flushing of, 137 pliance, $J25 gous stem cell transplant, 81 New products and services, 45, 110, 172, for infusion equipment, $J25 Home parenteral nutrition, complications of, 232, 297, 354 for infusion therapies, SJ58 74 Noncompliance, ethical aspects of, 266 for infusion-related complications, S58 Hyperemesis gravidarum, 89 Nursing education. See Education and training Nutrition, home parenteral, complications for nonvascular access devices, S$]58 I of, 74 for nursing interventions, $J58 IgM monoclonal gammopathy, IV im- for nursing practice, S$J12 munoglobulin for, SM21 P for patient care, $J18 Immune deficiencies, in children, 206 Parenteral biologic therapy, 63 for site care and maintenance, $]48 Inclusion body myositis, [V immunoglobulin Parenteral nutrition for site selection and device place- for, SM21 for hyperemesis gravidarum, 89 ment, $]37 Inflammatory neuropathies, IV immunoglob- in home care, complications of, 74 State of the Society Report, 192 ulin for, SM21 Peripheral intravenous catheters. See also StatLock securement device, 34, 225 Infliximab Catheter(s Stem cell transplantation, Hickman vs. pe for rheumatoid arthritis, 326 discontinuation of, Visual Infusion ripherally inserted central for vasculitis, 272 Phlebitis scale for, 338 catheter for, 81 Infusion Nurses Society Annual Meeting dwell times for, 14 Substance abuse, ethical aspects of, 266 2005 Financial Report, 195 management practices for, in Greek, Suture securement, vs. securement devices, 34 Chief Executive Officer’s Report, 197 Jordanian, and Australian teach- Syringes, for flushing, 137 Presidential Address, 204 ing hospitals, 101 State of the Society Report for, 192 Peripheral-short catheters. See also T Infusion nursing standards ot practice. See Catheter(s) Standards of practice securement devices for, 34, 225 Tape, vs. securement devices, 34, 225 Interleukin inhibitors, for rheumatoid arthri- Peripherally inserted central catheters. See Thrombocytopenia, heparin-induced, tis, 326 also Catheter(s) argatroban for, 318 Intravenous immunoglobulin in children, 28 Tocilizumab, for rheumatoid arthritis, 326 administration of, SM5 securement devices for, 34, 225 Total parenteral nutrition Canadian protocol recommenda- vs. Hickman catheters, for autologous for hyperemesis gravidarum, 89 tions for, 158 stem cell transplant, 81 in home care, complications of, 74 subcutaneous, SM15 Phlebitic peripheral intravenous catheter, re- Training. See Education and training for neurologic diseases, SM21 moval of, Visual Infusion Transplantation, stem cell, Hickman vs. pe- Phiebitis scale for, 338 ripherally inserted central J Phlebotomy training, virtual reality simula- catheter for, 81 Jordan, peripheral intravenous catheter man- tor vs. simulated limbs for, Tumor necrosis factor-@ inhibitors, for agement practices in, 101 214 rheumatoid arthritis, 326 Vol. 2% No. 6, November/December 2006 U Vasculitis, biologic infusion therapies for, 272 Vomiting Ventricular fibrillation, pharmacologic man in chemotherapy, 283 Umbilical catheters. See also Catheter(s) placement and complication manage aaggemeemnetn t ofo,f , I 147 severe, in prpergengannacnyc,y , 8¢ 9 ment for, 346 Viritrutaula l rearleailtiyt y sismiumlualtaotror,, vs. simulatetde d limbs, for phlebotomy training, 214 W V Visual Infusion Pyh leb>}i tis sc.a le,> for discontin . Wi77 skott-Aldrich syndrome, 206 uation of peripheral IV Vascular access devices, flushing techniques BARS, catheters, 338 for, 13 STATEMENT OF OWNERSHIP, MANAGEMENT, AND CIRCULATION (Act of August 12, 1970; Section 3685; Title 39 United States Code) Date of Filing—October 1, 2006. Title of Publication—Journalo f Infusion Nursing; Frequency of Issue— Bimonthly; Annual Subscription Price—$101.95; Location of Known Office of Publication—Lippincott Williams & Wilkins, Inc., 16522 Hunters Green Parkway, Hagerstown, MD 21740-2116; Location of the Headquarters or General Business Of- fices of the Publisher—Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Publisher—Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Editor—Mary Alexander, Infusion Nurses Society, 220 Norwood Park South, Norwood, MA 02062. Managing Editor—Randi Davis, Lippincott Williams & Wilkins, Inc., 530 Walnut Street, Philadelphia, PA 19106; Owner—Infusion Nurses Society, 315 Norwood Park South, Norwood, MA 02062; Known Bond Holders, Mortgagees, and other security holders owning or holding 1 percent or more of the total amount of bonds, mortgages, or other securities—None. A. Total no. of copies printed (net press run), average 7,266, actual 7,200. B. Paid and/or requested circulation 1. Paid/requested outside-county mail subscriptions stated on form 3541, average 6,175, actual 6,148; 2. Paid in-county subscriptions, none; 3. Sales through dealers and carriers, street vendors, counter sales, .and other non-USPS paid distribution, average 266, actual 270; 4. Other classes mailed through the USPS, none. C. Total paid and/or requested circulation [sum of B (1), (2), (3), and (4)], average 6,441, actual 6,418. D. Free distribution by mail (sam- ples, complimentary, and other free). Outside-county as stated on form 3541, average 255, actual 296; 2. In-county as stated on form 3541, none; 3. Orher classes mailed through the USPS, none. E. Free distribution outside the mail (carriers or other means), average 4, actual 9. F. Total free distribution (sum of D and E), average 259, actual 305. G. Total distribution (sum of C and F), average 6,700, actual 6,723. H. Copies not distributed, average 566, actual 477. I. Total (sum of G and H), average 7,266, actual 7,200. Percent paid and/or requested circulation, average 96.13%, actual 95.46%. I certify that the statements made by me above are correct and complete. Jeffrey Brown, Manager, Periodicals Operations. Journal of Infusion Nursing